Famous Scientific Papers Rejected Before Publication: 5 That Changed Science

In 1964, Peter Higgs submitted a two-page paper to the journal Physics Letters predicting the existence of the particle that would later bear his name. The paper was rejected. No review. Just a note that it didn't warrant publication.

Higgs added a paragraph, sent it to Physical Review Letters instead, and it was accepted. Forty-eight years later, the particle was experimentally confirmed at CERN. Higgs won the Nobel Prize in 2013.

The paper the first journal didn't want has been cited over 4,000 times.

Dan Shechtman discovered quasicrystals in 1982. His lab director told him to go read a textbook. He was asked to leave his research group. When he tried to publish, the paper was rejected from Journal of Applied Physics.

He got it published in Physical Review Letters in 1984. For years, the response ranged from skepticism to open mockery. Linus Pauling said "there is no such thing as quasicrystals, only quasi-scientists." Shechtman won the Nobel Prize in Chemistry in 2011.

Before CRISPR became the most talked-about technology in biology, Virginijus Šikšnys submitted a paper in 2012 demonstrating that Cas9 could be programmed to cut specific DNA sequences, a finding that would help launch the gene-editing revolution. Cell rejected it. The paper was ultimately published in PNAS months later, by which time Doudna and Charpentier had published their landmark paper in Science. Doudna and Charpentier won the 2020 Nobel Prize in Chemistry. Many scientists believe Šikšnys would have shared the prize if Cell hadn't delayed his work by months.

In the mid-2000s, Katalin Karikó and Drew Weissman submitted a paper to Nature showing that chemically modified mRNA could avoid triggering the body's immune defenses, a finding that would become the foundation of the Pfizer and Moderna COVID-19 vaccines. Nature desk rejected it, calling it an "incremental contribution."

The paper was published in Immunity in 2005. For years, almost nobody cited it. Karikó was demoted from her faculty position at Penn because her mRNA research was considered unproductive. Then a pandemic hit. In 2023, Karikó and Weissman won the Nobel Prize in Physiology or Medicine for the work Nature had called incremental.

In 1955, Rosalyn Yalow and Solomon Berson submitted a paper to the Journal of Clinical Investigation showing that the body produces antibodies against insulin: a finding that implied insulin was immunogenic, which contradicted accepted immunology. The journal's reviewers rejected this framing outright. Yalow and Berson were required to remove every instance of the word "antibody" from the paper before it would be published. The term "insulin-binding protein" was substituted throughout. Their data was unchanged.

The technique they developed to prove the finding: radioimmunoassay, the ability to measure vanishingly small concentrations of biological molecules using radioactive tracers: became one of the most widely used tools in medicine. In 1977, Rosalyn Yalow won the Nobel Prize in Physiology or Medicine (Berson had died in 1972 and could not be awarded posthumously). The word "antibody" now appears routinely in the published literature they helped create.

Barry Marshall and Robin Warren spent years trying to publish the evidence that peptic ulcers are caused by bacterial infection: specifically by a bacterium now called Helicobacter pylori. The scientific consensus at the time was that the stomach's acid environment was sterile. Bacteria simply could not survive there.

Their initial abstract, submitted to a Gastroenterological Society meeting in 1983, was rejected as one of the bottom-ranked submissions. When they managed to present, their data were met with disbelief. Marshall was so frustrated that in 1984 he drank a solution containing H. pylori, developed gastritis, documented it, and treated himself with antibiotics. The paper eventually appeared in The Lancet in 1984. In 2005, Marshall and Warren won the Nobel Prize in Physiology or Medicine. Standard treatment for peptic ulcers shifted from lifelong acid suppression to a one-week antibiotic course.

It's tempting to read these as "don't worry, rejection doesn't matter." That's not quite right. What they tell you is something more specific:

Desk rejection reflects journal fit, not scientific quality. The Higgs paper was rejected because it didn't match what that journal wanted at that moment. Not because the physics was wrong. Not because the evidence was weak. The Krebs cycle paper wasn't even read. Nature just had a full queue.

The same work can be perfect for one venue and wrong for another. Higgs added one paragraph and published elsewhere. Karikó's paper went from "incremental" at Nature to foundational in Immunity. The science didn't change. The targeting did.

Persistence matters, but blind persistence doesn't. None of these researchers just resubmitted the same paper to the same journal. They found a different home, one that was actually looking for what they had.

Timing isn't always in your control. Šikšnys's delay at Cell may have cost him a Nobel Prize. Karikó's work sat mostly uncited for over a decade before a pandemic proved its importance. Sometimes the world catches up to you.

If you just got desk rejected, you're in good company. The question isn't whether your work is good. It's whether you sent it to the right place at the right time. Figure that out, and try again.

The papers above share one thing: they were eventually published, and they changed their fields. But that outcome required the authors to keep submitting, often for years, to journals that recognised the work.

The lesson is not that desk rejection doesn't matter. It's that desk rejection from the wrong journal is survivable: and that the right journal for a paper is sometimes not the most obvious one.

But there is a harder lesson embedded in these stories too. Most of the time, papers that get desk rejected from high-tier journals do not become classics. They get revised, submitted to lower-tier journals, and published quietly. The authors who got desk rejected and eventually had landmark papers were working on landmark science. The method and the finding were genuinely extraordinary. The journals that rejected them were wrong.

For most researchers, the more useful question is not "could my paper be the next PCR story?" but "is my paper actually ready for the journal I am targeting, and if not, what would it take to get there?"

Desk rejection at a target journal is most useful as a signal when you understand what specifically triggered it. Scope mismatch is fixable: resubmit elsewhere. Novelty concerns are harder: they require either reframing or new experiments. Methods critiques are usually somewhere in between.

If you are not sure which category your desk rejection falls into, or you want to know whether your manuscript would face the same issue before you submit, a pre-submission review can answer that specifically.

A desk-rejection risk and scope fit check can identify whether your manuscript faces the same structural issues before you submit.

The five stories above plus the two additional cases give us seven. Here are three more documented rejections of work that went on to win Nobel Prizes, bringing the total to ten.

Fermi's paper on beta decay theory (the foundation of the weak nuclear force) was rejected by Nature in 1933 for being "too remote from physical reality." He published in an Italian journal and then in Zeitschrift fur Physik. Five years later he won the Nobel Prize in Physics. Prusiner's prion hypothesis was called heresy by mainstream virologists; reviewers at multiple journals rejected the idea that proteins alone could be infectious agents. It took 15 years from his first publication to the Nobel. Gurdon's nuclear transfer work (showing that a differentiated cell could be reprogrammed) faced years of disbelief and publication difficulty before becoming the foundation of cloning science. He waited 50 years for the Nobel, the longest gap on this list.

These ten cases aren't random bad luck. They reveal three structural problems in how scientific publishing handles genuinely new ideas, problems that still exist today.

The uncomfortable truth is that peer review is structurally biased against the most original work. The more a finding challenges existing knowledge, the harder it is to find reviewers who'll evaluate it fairly, because the qualified reviewers are the same people whose assumptions are being challenged. That hasn't changed since 1937.

What has changed is that researchers now have more options for getting work in front of the right audience. Preprint servers, open-access journals, and faster editorial processes mean a desk rejection doesn't create the same multi-year delays it used to. But the underlying dynamic, journals filtering for consensus-confirming work, is still the default mode. If your paper is genuinely ahead of its field, expect resistance. The question is whether you can find the right venue fast enough that the delay doesn't cost you credit.

Last verified: March 2026. Historical rejection accounts are sourced from Nobel Prize biographical lectures and published scientific histories cited below.